IPS Journal of Basic and Clinical Medicine
ISSN: 3115-5731
IPS J Basic & Clin Med, 2(4): 133-142 (2025)
DOI: https://doi.org/10.54117/ijbcm.v2i4.23

Epstein-Barr Virus: Structure, Pathogenesis, Diagnosis, and Management of Associated Diseases

Iheukwumere, I. H.[1], Iheukwumere, C. M.[2], Unaeze, B. C.[3], Ike, V. E.[4], Nnadozie, H. C.[1] and Onyema, S. O.[1]

[1]Department of Microbiology, Faculty of Natural Sciences, Chukwuemeka Odumegwu Ojukwu University, Anambra State, Nigeria.
[2]Department of Applied Microbiology & Brewing, Faculty of Biosciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.
[3]Department of Medical Sciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.
[4]Department of Microbiology, University of Agriculture and Environmental Sciences, Umuagwo, Imo State, Nigeria.

*Corresponding author email: ik.iheukwumere@coou.edu.ng./ ikpower2007@yahoo.com

Abstract

Epstein-Barr virus (EBV), or human herpesvirus 4, is a ubiquitous gammaherpesvirus that establishes lifelong infection in over 90% of the global adult population. It is characterized by a complex structure, including an envelope with glycoproteins crucial for cell entry, a tegument protein layer, and an icosahedral capsid surrounding a linear double-stranded DNA genome approximately 172 kb in size. Primary transmission occurs via saliva, earning it the nickname "the kissing disease." While initial infection in childhood is often asymptomatic, infection in adolescents and young adults frequently results in infectious mononucleosis, presenting with fever, pharyngitis, lymphadenopathy, and fatigue. A significant aspect of EBV's pathogenesis is its ability to establish latent infection in B-lymphocytes, with periodic reactivation. This latent state is a key driver of its association with several malignancies, including Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, and post-transplant lymphoproliferative disorder (PTLD). Diagnosis primarily relies on serological tests detecting antibodies against viral capsid antigen (VCA), early antigen (EA), and nuclear antigen (EBNA), with molecular methods like PCR used for viral load quantification, especially in immunocompromised patients. Treatment for most cases of infectious mononucleosis is supportive, as no specific antiviral therapy is routinely recommended. Management focuses on symptom relief with analgesics, antipyretics, and rest. For severe or complicated cases, such as PTLD, strategies include immunosuppression reduction and immunotherapy. Prevention remains centered on hygiene practices to limit salivary exposure, as no licensed vaccine is yet available. Ongoing research into vaccines and immunotherapies is critical for improving outcomes for EBV-associated diseases.

Keywords: Epstein-Barr virus, infectious mononucleosis, latency, oncogenesis, diagnosis

Article History
Received: 13 Sept 2025
Accepted: 28 Sept 2025
Published: 07 Oct 2025

Scan QR Code to view[1]

How to cite this paper: Iheukwumere, I. H., Iheukwumere, C. M., Unaeze, B. C., Ike, V. E., Nnadozie, H. C., & Onyema, S. O. (2023). Epstein-Barr Virus: Structure, Pathogenesis, Diagnosis, and Management of Associated Diseases. *IPS Journal of Basic and Clinical Medicine*, *2*(4), 133–142. https://doi.org/10.54117/ijbcm.v2i4.23

1. Introduction

Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpesvirus family that infects a large portion of the human population worldwide. Discovered in 1964 by Michael Anthony Epstein and Yvonne Barr, EBV is best known for causing infectious mononucleosis, also known as glandular fever or the "kissing disease." However, EBV infection can lead to a wide range of clinical outcomes, from asymptomatic infection to more severe conditions such as lymphoproliferative disorders and certain types of cancer. EBV is a double-stranded DNA virus that primarily infects B cells, but it can also infect other cell types, including epithelial cells and T cells. The virus enters host cells through binding of its envelope glycoproteins to specific receptors on the cell surface. Once inside the host cell, the viral DNA is replicated and the virus can establish a lifelong latent infection in the host, with periodic reactivation leading to viral shedding and potential transmission to new hosts (Shannon-Lowe et al., 2016).

Infection with EBV is usually asymptomatic in childhood, but in adolescence or young adulthood, it can manifest as infectious mononucleosis, characterized by symptoms such as fever, sore throat, swollen lymph nodes, and fatigue. The virus is primarily transmitted through the exchange of saliva, hence its nickname as the "kissing disease." Most cases of infectious mononucleosis are self-limiting and resolve within a few weeks, but in some individuals, particularly those with weakened immune systems, the infection can lead to more severe complications such as chronic fatigue syndrome, hepatitis, or neurologic manifestations. Furthermore, EBV has been implicated in the development of various malignancies, including Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, and certain subtypes of non-Hodgkin lymphoma. In these cases, EBV can drive the transformation of infected cells by altering signalling pathways, promoting cell proliferation, and evading immune surveillance. The exact mechanisms by which EBV contributes to oncogenesis are complex and involve both viral and host factors, including the expression of viral oncogenes and the dysregulation of host immune responses (Babcock et al., 2020).

1.1 History of Epstein Barr Virus

Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a common virus that infects the majority of the world's population. It was first discovered in 1964 by Dr. Michael Epstein and Dr. Yvonne Barr, who were researching a link between Burkitt lymphoma, a type of cancer found in Africa, and the presence of a herpesvirus. The virus was later found to be associated with infectious mononucleosis, also known as glandular fever, a common viral infection that affects mainly young adults and adolescents. EBV belongs to the herpesvirus family, known for its ability to establish latency in host cells, which means the virus can hide in the body and reactivate later. After initial infection, the virus remains latent in B lymphocytes and epithelial cells for life, occasionally reactivating to cause recurrent infections (Babcock et al . 2020).

Apart from mononucleosis, EBV has also been associated with various types of cancers, including Burkitt lymphoma, Hodgkin's lymphoma, nasopharyngeal carcinoma, and some cases of gastric cancer. The virus is mainly transmitted through saliva, which is why it is often referred to as the "kissing disease." It can also be spread through blood transfusions, organ transplantations, and through contact with contaminated objects. Most infections with EBV occur during childhood and go unnoticed or cause only mild symptoms. However, in adolescents and adults, the virus can cause infectious mononucleosis, characterized by symptoms such as sore throat, fatigue, swollen lymph nodes, and fever. The immune response to EBV infection is complex and involves the activation of various immune cells, including T cells, B cells, and natural killer cells. Although most individuals are able to control the infection and keep it in check, certain conditions, such as immunodeficiency or a weakened immune system, can lead to the virus reactivating and causing severe complications (Babcock et al ., 2020).

Apart from its role in infectious mononucleosis and cancer, recent studies have also suggested a possible link between EBV and other autoimmune diseases, such as lupus, multiple sclerosis, and rheumatoid arthritis. The exact mechanisms by which EBV contributes to these conditions are still being investigated, but it is believed to involve the virus's ability to dysregulate the immune system and trigger an abnormal response. In conclusion, the Epstein-Barr virus is a common virus that infects most of the world's population and can cause a range of illnesses, from mild symptoms to severe complications. Its discovery by Dr. Epstein and Dr. Barr in the 1960s paved the way for further research into the virus's role in various diseases, including cancer and autoimmune disorders. Understanding the history and biology of EBV is crucial for developing effective treatment strategies and prevention measures (Babcock et al., 2020).

1.2 Classifications of Epstein-Barr Virus

Order: Herpesvirales
Family: Herpesviridae
Subfamily: Gammaherpesvirinae
Genus: Lymphocryptovirus
Species: Epstein-Barr virus (EBV)
Vernacular name: Epstein-Barr virus (Rickinson, 2023)

Epstein-Barr virus (EBV) is a member of the Herpesviridae family, specifically classified under the Gammaherpesvirinae subfamily. Within the Herpesviridae family, the EBV belongs to the Lymphocryptovirus genus. This virus infects humans and is commonly known as Epstein-Barr virus (EBV)

2. Viral Structure of EBV

Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the *Herpesviridae* family, subfamily *Gammaherpesvirinae*, and is one of the most ubiquitous human viruses. It possesses a complex and highly organized structure characteristic of herpesviruses, which facilitates its ability to infect, replicate within, and establish latency in human cells—primarily B lymphocytes and epithelial cells.
The outermost component of EBV is its lipid envelope, which is derived from the host cell’s membrane during viral budding. Embedded within this envelope are several glycoproteins that play crucial roles in the virus’s ability to bind to and enter host cells. Among these glycoproteins, gp350/220 is the most abundant and is primarily responsible for attaching to the CD21 receptor on B cells. Other essential glycoproteins include gp42, gH/gL, and gB, which function in membrane fusion and entry into host cells. Notably, gp42 facilitates EBV entry into B lymphocytes by binding to the MHC class II molecules, while gH/gL and gB are necessary for fusion with the host membrane (Hutt-Fletcher, 2007).

Beneath the envelope lies the tegument, a protein-rich layer situated between the envelope and the capsid. The tegument contains various viral proteins that assist in the early stages of infection by modulating host cell processes and initiating the transcription of viral genes (Young and Rickinson, 2004). This layer plays a key role in shaping the intracellular environment to favor viral replication.

2.1 Genome Organization of EBV

The genome of EBV is a linear double-stranded DNA molecule approximately 172 kb in size. It is divided into two segments: a unique long (UL) region and a unique short (US) region, each flanked by terminal repeats. The EBV genome encodes around 80 genes, including both structural and nonstructural proteins. One of the key features of the EBV genome is its ability to establish lifelong latent infections in human B lymphocytes. During latency, the virus exists within the host cell without actively producing infectious particles, allowing it to evade the immune system and persist in a latent state. The latency-associated genes of EBV play essential roles in this process. These genes can be classified into different latency programs, including latency I, II, and III, based on the expression of viral genes and proteins (Babcock et al ., 2020). Accessory proteins encoded by the EBV genome are crucial for the virus's life cycle and immune evasion strategies. Some of these accessory proteins include EBNA1 (Epstein-Barr nuclear antigen 1), LMP1 (latent membrane protein 1), and LMP2A (latent membrane protein 2A). EBNA1 is essential for the maintenance of the viral episome in dividing cells and plays a role in viral transcription regulation. LMP1 is a membrane-bound protein that mimics CD40 signaling and is involved in cellular transformation, immune evasion, and cell survival. LMP2A, on the other hand, modulates B cell signaling pathways to establish latency and evade immune surveillance (Cohen, 2023).

Structural proteins of EBV are primarily responsible for the assembly of the viral particle and its entry into host cells. The major structural proteins of EBV include the capsid protein (VP26), the tegument proteins (pUL36 and pUL48), and the glycoproteins (gp350 and gB). The capsid protein VP26 is crucial for capsid formation, while the tegument proteins play a role in viral assembly and transport within the host cell. The glycoproteins are involved in viral attachment and entry into host cells, the Epstein-Barr virus genome is complex and versatile, with both accessory and structural proteins playing crucial roles in viral replication, latency establishment, and immune evasion. Understanding the functions of these proteins can provide valuable insights into the molecular mechanisms of EBV infection and help in the development of new therapeutic strategies against this important human pathogen (Rickinson, 2023).



Figure 1: Structure of Epstein-Barr Virus
Source: Cohen, (2023)



Figure 2: Genome Structure of Epstein-Barr Virus
Source: Babcock et al. (2020)

2.2 Properties of Epstein-Barr Virus

Physical Properties

1. EBV is an enveloped virus with an icosahedral capsid structure, measuring approximately 120-180 nm in diameter.
2. The virus contains a double-stranded DNA genome, approximately 172 kilobases in length, which encodes over 80 genes.
3. The viral envelope is derived from the host cell membrane and contains glycoproteins essential for cell entry.
4. EBV is relatively stable in the environment but can be inactivated by heat, UV light, and disinfectants.
5. The virus is primarily transmitted through saliva, which allows it to persist in the oropharyngeal epithelium (Cohen, 2000).

Chemical Properties

1. The viral envelope is rich in lipids derived from the host cell, which play a crucial role in membrane fusion and entry into host cells.
2. EBV expresses several glycoproteins (e.g., gp350, gp220) on its surface that are critical for binding to the CD21 receptor on B cells.
3. The viral DNA is associated with histones, forming a chromatin-like structure that can exist in a latent form within host cells.
4. EBV is sensitive to pH extremes and can be inactivated in acidic or alkaline conditions.
5. The virus encodes several enzymes, including DNA polymerase, which are essential for its replication within host cells (Cohen, 2000)

Biological Properties

1. EBV primarily infects human B lymphocytes but can also infect epithelial cells and other cell types.
2. After initial infection, EBV can establish latency in B cells, where it can persist for the lifetime of the host without causing disease.
3. The virus has evolved mechanisms to evade the host immune response, including downregulating MHC class I molecules.
4. EBV is linked to several diseases, including infectious mononucleosis, Burkitt lymphoma, Hodgkin lymphoma, and nasopharyngeal carcinoma.

5. EBV can reactivate from latency, particularly in immunocompromised individuals, leading to viral replication and potential disease (Cohen, 2000)

3. Transmission Mechanism

EBV is primarily transmitted through saliva, hence it is commonly referred to as the "kissing disease" or the "mono" virus. The virus is responsible for causing infectious mononucleosis, also known as glandular fever. EBV is highly contagious and is transmitted through various modes, including direct person-to-person contact, exchange of bodily fluids, and contact with contaminated surfaces. One of the primary modes of EBV transmission is through direct person-to-person contact. When an infected individual comes into close contact with a non-infected person, the virus can be transmitted through saliva or respiratory secretions. This can occur through activities such as kissing, sharing utensils, or coughing and sneezing in close proximity to others. The virus can also be transmitted through blood transfusions or organ transplants from infected donors (Young & Rickinson, 2024).

In addition to direct contact, EBV can also be transmitted through the exchange of bodily fluids. This includes sexual contact, such as vaginal, anal, or oral intercourse, as well as sharing needles or other contaminated equipment. The virus can also be present in breast milk, which can result in mother-to-child transmission during breastfeeding. Healthcare workers may also be at risk of EBV transmission through exposure to patients' bodily fluids or contaminated equipment. Furthermore, EBV can be transmitted through contact with contaminated surfaces or objects. The virus can survive outside the body for a short period, so touching surfaces or objects contaminated with infected bodily fluids can result in transmission. This can occur in settings such as schools, daycare centers, or healthcare facilities where individuals may come into contact with contaminated surfaces or objects (Harris, 2021).



Figure 3: Transmission Mechanism of Epstein-Barr Virus
Source: Harris, (2021)

3.1 Replication of Epstein-Barr Virus

Epstein-Barr virus (EBV) is a herpesvirus that infects humans and is associated with a range of diseases, including infectious mononucleosis, various types of lymphoma, and nasopharyngeal carcinoma. Like all herpesviruses, EBV has a complex life cycle that involves both lytic and latent phases. During lytic infection, the virus replicates and produces new virions that can infect other cells. In this article, we will discuss the steps involved in the replication of Epstein-Barr virus.

Attachment

The first step in the replication of EBV is attachment to the host cell. The virus attaches to specific receptors on the surface of the host cell, facilitating entry into the cell (Cohen, 2023; Iheukwumere *et al*., 2025a).

Penetration

Once attached, the virus enters the host cell through endocytosis or direct fusion with the cell membrane. The viral envelope fuses with the host cell membrane, releasing the viral capsid into the cytoplasm of the host cell (Cohen, 2000; Iheukwumere *et al*., 2025b).

Targeting the site of replication:

Once inside the host cell, the EBV capsid is transported to the nucleus, where viral replication will take place. EBV specifically targets B lymphocytes and epithelial cells for replication (Shannon-Lowe et al., 2016; Iheukwumere *et al*., 2025c).

Uncoating

After the viral capsid reaches the nucleus, the viral DNA is released from the capsid and becomes accessible for transcription and replication (Shannon-Lowe et al., 2016; Iheukwumere *et al*., 2025d).

Early transcription:

The viral DNA is transcribed by the host cell RNA polymerase, leading to the production of early viral mRNAs. These mRNAs encode proteins that are necessary for viral replication (Cohen, 2000; Iheukwumere *et al*., 2025e).

Early translation

The early viral mRNAs are translated by the host cell ribosomes, resulting in the production of proteins that are involved in viral replication, such as viral DNA polymerase (Cohen, 2023; Iheukwumere *et al*., 2025f).

Genome replication:

The viral DNA replicates using the host cell DNA polymerase, leading to the production of viral DNA genomes that will be packaged into new virions (Cohen, 2023; Iheukwumere *et al*., 2025g).

Late transcription: As viral DNA replication progresses, late viral mRNAs are transcribed. These mRNAs encode structural proteins that are necessary for the assembly of new virions (Cohen, 2023).

Late translation:

The late viral mRNAs are translated by the host cell ribosomes, resulting in the production of viral structural proteins, such as capsid proteins and envelope proteins (Cohen, 2023).

Assembly and maturation

The newly synthesized viral DNA genomes and structural proteins are assembled into new virions in the nucleus. The virions are then transported to the cell membrane, where they

bud out of the cell, acquiring an envelope derived from the host cell membrane (Cohen, 2023).

Release

The mature virions are released from the host cell, ready to infect new cells and continue the replication cycle. the replication of Epstein-Barr virus involves a series of complex steps that allow the virus to infect and replicate in host cells. Understanding the molecular mechanisms involved in EBV replication is crucial for the development of novel antiviral strategies to target this virus. Further research into the replication of EBV will help improve our understanding of the virus's pathogenesis and facilitate the development of new treatments for EBV-associated diseases (Cohen, 2000).



Figure 4: Replication cycle of Epstein-Barr Virus
Source: Cohen, (2023)

3.2 PATHOGENESIS OF EPSTEIN-BARR VIRUS

Epstein-Barr virus (EBV) is a member of the herpesvirus family and is known to cause infectious mononucleosis, as well as being linked to several other diseases, including certain cancers.

Entry of the virus into the host:

EBV typically enters the host through the oral cavity, where it infects B cells in the oropharynx and tonsils. The virus can also enter through other routes, such as blood transfusion or organ transplantation. Initial infection is often asymptomatic, but in some cases, it can lead to the development of infectious mononucleosis or other diseases (Niedobitek et al., 2021; Iheukwumere *et al*., 2024a).

Contact with susceptible cells:

EBV primarily infects B cells but can also infect epithelial cells and other cell types. The virus targets cells expressing the CD21 receptor, which is present on B cells and certain epithelial cells. Once inside the host cell, the virus replicates and establishes a latent infection (Young et al., 2024; Iheukwumere *et al*., 2024b).

Replication within the cells:

After entering the host cell, EBV releases its genetic material into the nucleus and utilizes the host cell machinery to replicate. The virus can either undergo lytic replication, where it produces new viral particles that are released to infect other cells, or establish a latent infection, where the viral genome persists in the host cell without producing new virions (Niedobitek et al., 2021; Iheukwumere *et al*., 2024c).

Release from host cells:

During lytic replication, EBV assembles new viral particles in the host cell and subsequently releases them to infect neighboring cells. The release of viral particles can lead to the spread of the infection to other tissues and organs (Young et al., 2024; Iheukwumere *et al*., 2024d).

Viral spread and host tropism:

EBV has a broad tissue tropism and can infect a variety of cell types, including B cells, T cells, epithelial cells, and others. The virus can spread throughout the body via the bloodstream or infected cells, leading to systemic infection and dissemination to different organs (Niedobitek et al., 2021; Iheukwumere *et al*., 2024e).

Cell injury and clinical illness:

EBV infection can lead to cell injury and trigger immune responses, which can result in symptoms such as fever, sore throat, swollen lymph nodes, and fatigue. In some cases, EBV infection can progress to infectious mononucleosis or other complications, such as lymphoproliferative disorders or certain cancers, particularly in immunocompromised individuals (Münz 2019; Iheukwumere *et al*., 2024f).

Recovery from infection

In most cases, the immune system is able to control and eventually clear the EBV infection. However, the virus can establish a lifelong latent infection in B cells, which can reactivate under certain conditions, such as immunosuppression or stress. Repeated reactivation of EBV can contribute to the development of chronic diseases and malignancies (Niedobitek et al., 2021).

Viral shielding:

EBV has evolved various strategies to evade the immune response and establish persistent infection. This includes the expression of viral proteins that modulate immune signaling pathways, inhibit apoptosis, and promote cell survival. The virus can also establish a latent state in infected cells, where it remains hidden from immune surveillance. the pathogenesis of Epstein-Barr virus involves a complex interplay between the virus and the host immune system, leading to a spectrum of clinical manifestations and outcomes. Understanding the mechanisms by which EBV infects cells, replicates, and evades immune responses is essential for developing effective therapies and vaccines to prevent EBV-associated diseases (Münz 2019)

3.3 Diseases Associated with Epstein-Barr Virus

Infectious Mononucleosis (IM)

Infectious mononucleosis is the most well-known clinical manifestation of primary EBV infection, particularly in adolescents and young adults. It is often referred to as the "kissing disease" due to its mode of transmission through saliva. The illness typically presents with fever, sore throat,

lymphadenopathy, fatigue, and hepatosplenomegaly. Although generally self-limiting, symptoms can persist for weeks to months in some cases. The disease is characterized by atypical lymphocytosis and a robust immune response to infected B cells (Dunmir et al., 2015).

Burkitt Lymphoma
EBV is strongly associated with endemic Burkitt lymphoma, particularly in equatorial Africa and Papua New Guinea. This aggressive B-cell non-Hodgkin lymphoma primarily affects children and often presents as a jaw or facial bone tumor. EBV plays a critical role in the pathogenesis by promoting chromosomal translocation involving the *MYC* oncogene, leading to uncontrolled B cell proliferation (Thorley-Lawson and Gross, 2004).

Hodgkin Lymphoma
A significant proportion of classical Hodgkin lymphoma (especially the mixed-cellularity and lymphocyte-depleted subtypes) is associated with EBV. The virus is present in the Reed-Sternberg cells, the malignant B cells in Hodgkin lymphoma. EBV infection contributes to the transformation and survival of these cells through the expression of latent membrane protein 1 (LMP1), a functional homolog of the CD40 receptor (Kuppers, 2009).

Nasopharyngeal Carcinoma (NPC)
Nasopharyngeal carcinoma, particularly the undifferentiated non-keratinizing subtype, has a strong link to EBV, especially in Southeast Asia and parts of North Africa. The virus plays a direct oncogenic role by expressing proteins such as LMP1 and Epstein-Barr nuclear antigen 1 (EBNA1), which contribute to cellular transformation and immune evasion. Early diagnosis of NPC often relies on EBV serology and detection of EBV DNA in plasma (Young and Rickinson, 2004).

Post-Transplant Lymphoproliferative Disorder (PTLD)
In immunocompromised individuals, particularly organ or stem cell transplant recipients, EBV can cause post-transplant lymphoproliferative disorder. This condition encompasses a spectrum from benign polyclonal lymphoid hyperplasia to aggressive monoclonal lymphomas. The risk is highest in individuals with primary EBV infection post-transplant due to reduced immune surveillance (Opelz and Döhler, 2004).

Oral Hairy Leukoplakia
Oral hairy leukoplakia is a benign, EBV-associated lesion typically found on the lateral tongue in immunocompromised individuals, particularly those with HIV/AIDS. It is characterized by white, corrugated plaques and is the result of productive EBV replication in epithelial cells (Greenspan et al., 1985).

Chronic Active EBV Infection (CAEBV)
Chronic active EBV infection is a rare condition characterized by persistent symptoms of EBV infection, such as fever, lymphadenopathy, hepatosplenomegaly, and high viral loads. It may progress to lymphomas or hemophagocytic lymphohistiocytosis (HLH), especially in individuals with immune dysfunction (Kimura et al., 2001).

Autoimmune Diseases
There is growing evidence linking EBV to the development of autoimmune diseases, such as multiple sclerosis (MS), systemic lupus erythematosus (SLE), and rheumatoid arthritis. EBV may contribute through molecular mimicry, bystander activation, or latent infection of autoreactive B cells, leading to chronic immune dysregulation (Bjornevik et al., 2022).
.

3.4 Clinical Manifestation
Epstein-Barr virus (EBV), or human herpesvirus 4, is a ubiquitous herpesvirus that infects more than 90% of the global population. The clinical manifestations of EBV vary widely, ranging from asymptomatic infections to acute and chronic diseases, depending on the age of the host, immune status, and genetic predispositions. EBV primarily infects B lymphocytes and epithelial cells, and its effects are mediated through both lytic and latent viral cycles (Young and Rickinson, 2004).

1. Asymptomatic Infection
In most individuals, particularly young children, primary EBV infection is asymptomatic or causes only mild symptoms resembling a common viral illness. These cases often go undiagnosed, and the virus establishes lifelong latency in B cells (Dunmire et al., 2015).

2. Infectious Mononucleosis
In adolescents and young adults, primary EBV infection more commonly presents as **infectious mononucleosis (IM)**. This condition is characterized by:

- Fever
- Pharyngitis (sore throat)
- Lymphadenopathy (especially posterior cervical nodes)
- Splenomegaly (enlarged spleen)
- Fatigue and malaise
- Atypical lymphocytosis (observed in blood smear)

These symptoms typically resolve within 2–4 weeks, although fatigue may persist for several months. Complications can include splenic rupture, hepatitis, hemolytic anemia, and airway obstruction (Balfour et al., 2013).

3. Lymphoproliferative Disorders
In immunocompromised individuals—such as those undergoing organ transplants or with congenital immunodeficiencies—EBV can cause **post-transplant lymphoproliferative disorder (PTLD)**. This spectrum of disease ranges from benign polyclonal proliferation to malignant lymphoma due to uncontrolled EBV-driven B-cell expansion (Opelz and Döhler, 2004).

4. Malignancies
EBV is associated with several malignancies:

- **Burkitt lymphoma** (endemic type): Presents as a rapidly growing tumor, commonly in the jaw or abdomen, especially in African children.
- **Hodgkin lymphoma**: EBV-positive in many mixed cellularity and lymphocyte-depleted subtypes.
- **Nasopharyngeal carcinoma**: Common in Southeast Asia and associated with EBV DNA in tumor cells.

- **Gastric carcinoma**: A subset of gastric cancers is EBV-associated and shows distinct molecular features (Young and Rickinson, 2004).

5. Chronic Active EBV Infection (CAEBV)

CAEBV is a rare but serious condition characterized by:

- Persistent fever
- Hepatosplenomegaly
- Lymphadenopathy
- High viral loads
- Organ dysfunction

It may lead to life-threatening complications such as hemophagocytic lymphohistiocytosis (HLH), lymphoma, or multiorgan failure (Kimura et al., 2001).

6. Oral Hairy Leukoplakia

In individuals with severe immunosuppression, particularly those with HIV/AIDS, EBV can cause **oral hairy leukoplakia**—a non-painful, white, corrugated lesion on the lateral border of the tongue, resulting from EBV replication in epithelial cells (Greenspan et al., 1985).

7. Neurological Manifestations

Although rare, EBV can cause neurological complications, including:

- Meningitis
- Encephalitis
- Guillain-Barré syndrome
- Transverse myelitis
- Cranial nerve palsies

These complications are more common in immunocompromised individuals and may occur during either primary infection or reactivation (Miller et al., 2010).

8. Autoimmune Disorders

EBV has been implicated in the pathogenesis of autoimmune diseases such as:

- **Systemic lupus erythematosus (SLE)**
- **Multiple sclerosis (MS)**
- **Rheumatoid arthritis**

This association is thought to involve molecular mimicry, latent infection of autoreactive B cells, and chronic immune stimulation (Bjornevik et al., 2022).

4. Distribution of Epstein-Barr Virus

The distribution of EBV is widespread, with the virus being found in people of all ages, races, and geographical locations. In this write-up, we will explore the distribution of Epstein-Barr virus in terms of people, place, and period (Cohen et al., 2020).

People

EBV infects people of all ages, but the primary infection usually occurs during childhood or adolescence. The virus is mainly transmitted through saliva, hence the nickname "the kissing disease." Once a person is infected with EBV, the virus remains dormant in the body and can reactivate periodically throughout their lifetime. EBV is most commonly associated with infectious mononucleosis, a condition characterized by symptoms such as fever, sore throat, swollen lymph nodes, and fatigue. In addition to mononucleosis, EBV has been linked to several other diseases, including certain types of lymphomas and carcinomas (Shannon-Lowe et al., 2017). Certain populations are at higher risk of EBV-related complications. For example, individuals with weakened immune systems, such as those undergoing organ transplants or living with HIV/AIDS, are more susceptible to developing severe EBV-associated diseases. Additionally, in parts of Africa and Southeast Asia, EBV has been implicated in the development of Burkitt's lymphoma, a type of cancer commonly found in children (Shannon-Lowe et al., 2017).

Place

The distribution of EBV is global, with the virus found in populations across all continents. Studies have shown that the seroprevalence of EBV varies by region, with higher rates of infection observed in developing countries compared to industrialized nations. In some parts of the world, such as sub-Saharan Africa, the prevalence of EBV is nearly universal, with the majority of individuals becoming infected during childhood. This high prevalence has been linked to the increased incidence of EBV-associated cancers, such as Burkitt's lymphoma and nasopharyngeal carcinoma, in these regions (Shannon-Lowe et al., 2017).

Period

Epstein-Barr virus was first discovered in 1964 by Dr. Michael Epstein and Dr. Yvonne Barr, who identified the virus in cultured tumor cells taken from patients with Burkitt's lymphoma. Since its discovery, research on EBV has expanded, shedding light on the virus's pathogenesis, epidemiology, and clinical manifestations. The timeline of EBV research has revealed important insights into the virus's distribution and impact on human health.the distribution of Epstein-Barr virus is widespread, with the virus infecting people of all ages and races in various geographical locations. While EBV is generally asymptomatic in healthy individuals, it can cause severe complications in certain populations, particularly those with compromised immune systems. Understanding the epidemiology of EBV is crucial for developing strategies to prevent and manage the associated diseases. Further research is needed to elucidate the complex interactions between EBV and its host and to develop effective therapies for EBV-related conditions (Lerner et al., 2017).

4.1 Laboratory Diagnosis

The diagnosis of Epstein-Barr virus (EBV) infection typically involves a multi-faceted approach that includes clinical evaluation, sample collection, serological testing, viral culture, and molecular analysis. Accurate identification of EBV is essential for effective patient management, especially in cases where the infection may progress to more serious complications such as lymphoproliferative disorders or malignancies.

Clinical Evaluation and Physical Examination

The diagnostic process often begins with a thorough physical examination. Patients suspected of EBV infection commonly present with symptoms such as fever, sore throat, lymphadenopathy, fatigue, and splenomegaly. These clinical signs, particularly in the presence of a history of recent

exposure to infected individuals, may prompt further investigation (Lee et al., 2020).

Sample Collection

The diagnostic accuracy of EBV detection depends significantly on appropriate sample collection. Blood samples are most commonly used to detect serological markers of infection, such as specific antibodies. In addition, saliva and throat swabs may be collected to assess for active viral shedding or to attempt culture of the virus (Lee et al., 2020). Blood samples are essential for both serological assays and molecular diagnostics (Iheukwumere *et al*., 2025h).

Sample Transportation

Proper sample transportation is critical to maintain the integrity of clinical specimens. Blood samples should be collected in sterile containers with anticoagulants and maintained at room temperature until analysis. Similarly, saliva and throat swab samples should be transported in virus transport medium or collection devices as per laboratory protocols to preserve viral integrity for downstream testing (Niederman et al., 2018).

Serological Testing

Serological testing remains one of the most commonly used methods for diagnosing EBV infection. The heterophile antibody test, also known as the Monospot test, is widely used for rapid diagnosis, particularly in cases of infectious mononucleosis. More specific assays measure antibodies directed against EBV viral capsid antigen (VCA), early antigen (EA), and Epstein-Barr nuclear antigen (EBNA). The detection of VCA-IgM indicates recent infection, whereas the presence of VCA-IgG and EBNA-IgG typically suggests past infection (Niederman et al., 2018; Iheukwumere *et al*., 2025i).

Viral Culture

Although culturing EBV can provide definitive diagnosis, it is rarely performed in routine clinical settings due to the virus's slow replication cycle and the requirement for specialized culture systems. EBV is typically cultured in B-cell lines that support its replication, such as those derived from lymphoblastoid cells. Due to these limitations, culture is mainly used in research or for confirmatory purposes in specialized laboratories (Lee et al., 2020; Iheukwumere *et al*., 2025j).

Molecular Techniques

Molecular diagnostics, especially polymerase chain reaction (PCR), offer high sensitivity and specificity for the detection of EBV DNA in clinical specimens. PCR is particularly valuable in cases where serological tests yield inconclusive results or where a rapid diagnosis is critical. Quantitative PCR is also useful in monitoring EBV viral load in immunocompromised patients, such as transplant recipients or individuals with EBV-associated malignancies (Li, 2023).

4.2 Treatment of Epstein-Barr Virus

The treatment of Epstein-Barr virus (EBV) infection primarily focuses on symptomatic management, as there is currently no specific antiviral therapy approved for routine clinical use against EBV. The approach to treatment varies depending on the severity of the infection and whether the patient develops complications such as infectious mononucleosis or EBV-associated malignancies. While most EBV infections are self-limiting, individuals with compromised immune systems or EBV-associated cancers may require more intensive and targeted interventions.

Supportive Care for Uncomplicated EBV Infection

In the majority of cases, especially during primary EBV infection that results in infectious mononucleosis, treatment is supportive. Common recommendations include rest, hydration, and the use of analgesics and antipyretics such as acetaminophen or ibuprofen to alleviate fever, sore throat, and malaise (Luzuriaga and Sullivan, 2010). Corticosteroids may be considered in patients with severe tonsillar hypertrophy causing airway obstruction, hemolytic anemia, or thrombocytopenia, although their use remains controversial and should be reserved for serious complications (Balfour et al., 2013).

Antiviral Therapy

Several antiviral agents, including acyclovir, ganciclovir, and valacyclovir, have shown some in vitro activity against EBV by inhibiting viral DNA polymerase. However, clinical trials have generally failed to demonstrate significant benefit in treating uncomplicated infectious mononucleosis (Straus et al., 1988). Acyclovir has been shown to reduce viral shedding in the oropharynx but does not significantly alter the clinical course of the disease. Therefore, antiviral therapy is not routinely recommended for immunocompetent individuals with primary EBV infection (De Paor et al., 2016).

Management of EBV-Associated Complications

In immunocompromised individuals, such as transplant recipients, EBV can lead to serious complications including post-transplant lymphoproliferative disorder (PTLD). Management strategies in these patients may include reduction of immunosuppression, administration of rituximab (a monoclonal anti-CD20 antibody), or cytotoxic chemotherapy depending on disease severity (Choquet et al., 2007). In certain EBV-associated malignancies such as nasopharyngeal carcinoma or Burkitt lymphoma, treatment usually involves chemoradiotherapy, and in some cases, experimental approaches such as EBV-specific cytotoxic T-cell therapy have shown promise (Gottschalk et al., 2005).

Immunotherapy and Experimental Approaches

Given EBV's ability to persist in a latent state and evade immune detection, immunotherapeutic strategies are under development. These include the use of adoptive T-cell transfer, therapeutic vaccines, and immune checkpoint inhibitors targeting the programmed death (PD-1) pathway, especially in the treatment of EBV-related cancers. While not yet widely available, these strategies are being explored in clinical trials and offer hope for managing chronic or malignant EBV infections in the future (Kimura and Cohen, 2017).

4.2 Prevention

1. Practice good hygiene: EBV is spread through saliva, so it's important to avoid sharing drinking glasses, utensils, or toothbrushes with others. Wash your hands frequently

with soap and water, especially after coming into contact with someone who is sick.

2. Avoid close contact with individuals who are infected: EBV is most commonly spread through close personal contact, so try to avoid kissing or sharing food with someone who has mono or other symptoms of an EBV infection.
3. Boost your immune system: A strong immune system can help protect you from viral infections like EBV. Make sure to get plenty of rest, stay hydrated, and eat a healthy diet rich in fruits, vegetables, and whole grains.
4. Practice safe sex: EBV can also be spread through sexual contact, so it's important to use protection during sexual activity to reduce your risk of infection.
5. Get vaccinated: While there is no specific vaccine for EBV, getting vaccinated against other viruses like the flu can help reduce your overall risk of infection and strengthen your immune system (Shannon-Lowe et al.,2016)

5. Conclusion

Epstein-Barr virus (EBV) is a highly prevalent human herpesvirus that establishes lifelong latency and can lead to a range of clinical manifestations, from mild infectious mononucleosis to serious malignancies. Early diagnosis, supportive treatment, and preventive strategies such as good hygiene practices and future vaccine development are crucial in managing EBV-related diseases.

References

Babcock, G. J., Decker, L. L., Volk, M., and Thorley-Lawson, D. A. (2020). EBV persistence in memory B cells in vivo. *Immunity*, *9*(3), 395–404.

Balfour, H. H., Hokanson, K. M., Schacherer, R. M., Griesemer, D., Schmeling, D. O., and Thomas, W. (2013). A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. *The Journal of Infectious Diseases*, *208*(8), 1286–1294. https://doi.org/10.1093/infdis/jit315

Bjornevik, K., Cortese, M., Healy, B. C., Kuhle, J., Mina, M. J., Leng, Y., … and Ascherio, A. (2022). Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science*, *375*(6578), 296–301.

Choquet, S., Leblond, V., Herbrecht, R., Socié, G., Stoppa, A. M., Viret, F., … and Oksenhendler, E. (2007). Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. *Blood*, *110*(2), 305–310. https://doi.org/10.1182/blood-2006-12-064683

Cohen, J. I. (2000). Epstein-Barr virus infection. *New England Journal of Medicine*, *343*(7), 481–492.

Cohen, J. I. (2015). Epstein–Barr virus vaccines. *Clinical and Translational Immunology*, *4*(1), e32.

Cohen, J. I. (2023). Epstein-Barr virus. In D. M. Knipe and P. M. Howley (Eds.), *Fields Virology* (6th ed., pp. 1898–1959). Lippincott Williams and Wilkins.

De Paor, M., O'Brien, K., Fahey, T., and Smith, S. M. (2016). Antiviral agents for infectious mononucleosis (glandular fever). *Cochrane Database of Systematic Reviews*, *2016*(12), CD011487. https://doi.org/10.1002/14651858.CD011487.pub2

Dunmire, S. K., Hogquist, K. A., and Balfour, H. H. (2015). Infectious mononucleosis. *Current Topics in Microbiology and Immunology*, *390*, 211–240.

Gottschalk, S., Heslop, H. E., and Rooney, C. M. (2005). Adoptive immunotherapy for Epstein-Barr virus-associated malignancies. *Annual Review of Medicine*, *56*, 387–404. https://doi.org/10.1146/annurev.med.56.062904.144223

Greenspan, D., Greenspan, J. S., Lennette, E. T., Abrams, D. I., Conant, M. A., Petersen, V., and Freese, U. K. (1985). Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. *New England Journal of Medicine*, *313*(25), 1564–1571.

Harris, N. L. (2011). The pathogenesis of Epstein-Barr virus-associated lymphoproliferative disorders. *Nature Reviews Immunology*, *11*(1), 1–12.

Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Iheunatuoha, U.A., Nwakoby, N.E. and Ilechukwu, C.C. (2025a). Enhancement of the antiviral potency of *Curcuma longa* and *Azadiratcha indica* using Vitamin C in embryonated chicken eggs. *IPS Journal of Phytochemistry and Chemistry and Medicinal Plant Research* 1(1): 9 – 14.

Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Iheunatuoha, U.A., Nwakoby, N.E., Ilechukwu, C.C. and Destiny, C.C. (2025b). Mitigating Newcastle Disease Virus induced damage in chicken embryos using extracts of *Curcuma longa* and *Baphia nitida. IPS Journal of Basic and Clinical Medicine* 2(2): 58 – 63.

Iheukwumere, I.H., Mmaduagha, C.P., Nwike, M.I., Iheukwumere, C.M., Ike, V.E., Obianom, A.O., Ihenatuoha, U.A., Igboanugo, E.U., Okereke, F.O., Obiefuna, O.H., Nwakoby, N.E., Ilechukwu, C.C., Ochibulu, S.C. and Ejike, C.E. (2025c). Mitigating Newcastle Disease Virus Pathogenesis with Allicumin: A patenting approach. *IPS Journal of Advanced and Applied Biochemistry* 1(1): 11 – 18.

Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Unaeze, B.C., Ejike, C.E., Igiri, V.C. and Okereke, F.O. (2024a). Augmenting the antiviral potency of *Baphia nitida* extract against Newcastle disease virus using Vitamin C using embryonated chicken eggs. *Tropical Journal of Applied Natural Scences.* 2(1): 1 – 12.

Iheukwumere, C.M., Iheukwumere, I.H. Obianom, A.O., Unaeze, B.C., Ejike, C.E., Igiri, V.C. and Okereke, F.O. (2024b). Supersizing the neutralizing activities of *Curcuma longa* and *Baphia nitida* extracts against Newcastle disease virus using Vitamin C. *Tropical Journal of Applied Natural Sciences* 2(1): 1 – 15.

Iheukwumere, C.M., Iheukwumere, I.H. Obianom, A.O., Unaeze, B.C., Ejike, C.E., Igiri, V.C. and Okereke, F.O. (2024c). Boosting the antiviral activity *Baphia nitida* leaves extract in broiler chicks using chicks Vitamin C. *Tropical Journal of Applied Natural Sciences* 2(1): 1 – 10.

Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Ihenatuoha, U.A., Nwakoby, N.E., Ilechukwu, C.C. and Destiny, E.C (2025d). *IPS Journal of Toxicology* 3(2): 55 – 59.

Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Ihenatuoha, U.A., Nwakoby, N.E. and Ilechukwu, C.C. (2025e). Minifying the effects of Newcastle Disease Virus on Structural development of chicken embryo using *Curcuma longa* and *Baphia nitida* extracts. *IPS Journal of Basic and Clinical Medicine* 2(2): 58 – 63.

Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Iheunatuoha, U.A., Nwakoby, N.E. and Ilechukwu, C.C. (2025f). Enhancement of the antiviral potency of

Curcuma longa and *Azadiratcha indica* using Vitamin C in embryonated chicken eggs. *IPS Journal of Phytochemistry and Chemistry and Medicinal Plant Research* 1(1): 9 – 14.

Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Iheunatuoha, U.A., Nwakoby, N.E., Ilechukwu, C.C. and Destiny, C.C. (2025g). Mitigating Newcastle Disease Virus induced damage in chicken embryos using extracts of *Curcuma longa* and *Baphia nitida*. *IPS Journal of Basic and Clinical Medicine* 2(2): 58 – 63.

Iheukwumere, I.H., Mmaduagha, C.P., Nwike, M.I., Iheukwumere, C.M., Ike, V.E., Obianom, A.O., Ihenatuoha, U.A., Igboanugo, E.U., Okereke, F.O., Obiefuna, O.H., Nwakoby, N.E., Ilechukwu, C.C., Ochibulu, S.C. and Ejike, C.E. (2025h). Mitigating Newcastle Disease Virus Pathogenesis with Allicumin: A patenting approach. *IPS Journal of Advanced and Applied Biochemistry* 1(1): 11 – 18.

Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Unaeze, B.C., Ejike, C.E., Igiri, V.C. and Okereke, F.O. (2024d). Augmenting the antiviral potency of *Baphia nitida* extract against Newcastle disease virus using Vitamin C using embryonated chicken eggs. *Tropical Journal of Applied Natural Scences.* 2(1): 1 – 12.

Iheukwumere, C.M., Iheukwumere, I.H. Obianom, A.O., Unaeze, B.C., Ejike, C.E., Igiri, V.C. and Okereke, F.O. (2024e). Supersizing the neutralizing activities of *Curcuma longa* and *Baphia nitida* extracts against Newcastle disease virus using Vitamin C. *Tropical Journal of Applied Natural Sciences* 2(1): 1 – 15.

Iheukwumere, C.M., Iheukwumere, I.H. Obianom, A.O., Unaeze, B.C., Ejike, C.E., Igiri, V.C. and Okereke, F.O. (2024f). Boosting the antiviral activity *Baphia nitida* leaves extract in broiler chicks using chicks Vitamin C. *Tropical Journal of Applied Natural Sciences* 2(1): 1 – 10.

Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Ihenatuoha, U.A., Nwakoby, N.E., Ilechukwu, C.C. and Destiny, E.C (2025i). *IPS Journal of Toxicology* 3(2): 55 – 59.

Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Ihenatuoha, U.A., Nwakoby, N.E. and Ilechukwu, C.C. (2025j). Minifying the effects of Newcastle Disease Virus on Structural development of chicken embryo using *Curcuma longa* and *Baphia nitida* extracts. *IPS Journal of Basic and Clinical Medicine* 2(2): 58 – 63.

Kieff, E., and Rickinson, A. B. (2017). Epstein-Barr virus and its associated diseases. In D. M. Knipe and P. M. Howley (Eds.), *Fields Virology* (5th ed.). Lippincott Williams and Wilkins.

Kimura, H., and Cohen, J. I. (2017). Chronic active Epstein-Barr virus disease. *Frontiers in Immunology*, *8*, 1867. https://doi.org/10.3389/fimmu.2017.01867

Kimura, H., Ito, Y., Kawabe, S., Gotoh, K., Takahashi, Y., Kojima, S., … and Morishima, T. (2001). EBV-associated T/NK-cell lymphoproliferative diseases in non-immunocompromised hosts: Prospective analysis of 108 cases. *Blood*, *98*(6), 2187–2194.

Klein, G., and Raab-Traub, N. (2015). Epstein-Barr virus: A model for the study of virus-host interactions. *Nature Reviews Microbiology*, *13*(1), 1–15.

Kuppers, R. (2009). The biology of Hodgkin's lymphoma. *Nature Reviews Cancer*, *9*(1), 15–27.

Lee, S. K., Kim, H. S., and Park, J. H. (2020). Diagnostic approaches for Epstein-Barr virus infection: Current status and future perspectives. *Journal of Clinical Virology*, *123*, 104245. https://doi.org/10.1016/j.jcv.2020.104245

Li, X. (2023). Advances in molecular diagnostics of Epstein-Barr virus-associated diseases. *Virology Journal*, *20*(1), 29. https://doi.org/10.1186/s12985-023-02034-0

Luzuriaga, K., and Sullivan, J. L. (2010). Infectious mononucleosis. *The New England Journal of Medicine*, *362*(21), 1993–2000. https://doi.org/10.1056/NEJMcp1001116

Miller, S., Kennedy, J. L., and Alperin, J. B. (2010). Neurologic complications of Epstein-Barr virus infection. *Pediatric Neurology*, *42*(5), 309–318.

Münz, C. (2019). Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. *Nature Reviews Microbiology*, *17*(11), 691–700.

Murata, T. (2014). Regulation of Epstein–Barr virus reactivation from latency. *Microbiology and Immunology*, *58*(6), 307–317.

Niederman, J. C., Luzuriaga, K., and Sullivan, J. L. (2018). Epstein-Barr virus. In D. M. Knipe and P. M. Howley (Eds.), *Fields Virology* (6th ed., pp. 1898–1959). Lippincott Williams and Wilkins.

Niedobitek, G., Meru, N., and Delecluse, H. J. (2021). Epstein-Barr virus infection and human malignancies. *International Journal of Experimental Pathology*, *82*(3), 149–170.

Opelz, G., and Döhler, B. (2004). Lymphomas after solid organ transplantation: A collaborative transplant study report. *American Journal of Transplantation*, *4*(2), 222–230.

Rickinson, A. B., and Kieff, E. (2023). Epstein-Barr virus. In D. M. Knipe and P. M. Howley (Eds.), *Fields Virology* (6th ed.). Lippincott Williams and Wilkins.

Shannon-Lowe, C. D., Neuhierl, B., Baldwin, G., Rickinson, A. B., and Delecluse, H. J. (2016). Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. *Proceedings of the National Academy of Sciences*, *103*(18), 7065–7070.

Shannon-Lowe, C., Rickinson, A. B., and Bell, A. I. (2017). Epstein-Barr virus-associated lymphomas. *Philosophical Transactions of the Royal Society B: Biological Sciences*, *372*(1732), 20160271.

Straus, S. E., Cohen, J. I., Tosato, G., and Meier, J. (1988). NIH conference: Epstein-Barr virus infections: Biology, pathogenesis, and management. *Annals of Internal Medicine*, *109*(4), 304–318. https://doi.org/10.7326/0003-4819-109-4-304

Thorley-Lawson, D. A., and Gross, A. (2004). Persistence of the Epstein-Barr virus and the origins of associated lymphomas. *New England Journal of Medicine*, *350*(13), 1328–1337.

Young, L. S., and Rickinson, A. B. (2004). Epstein-Barr virus: 40 years on. *Nature Reviews Cancer*, *4*(10), 757–768.